Literature DB >> 11758789

Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis.

M Wataya-Kaneda1, Y Kaneda, O Hino, H Adachi, Y Hirayama, K Seyama, T Satou, K Yoshikawa.   

Abstract

Tuberous sclerosis complex (TSC) is a multisystemic disorder characterized by systemic hamartomas. Although the disease-determining genes TSC1 and TSC2 have been isolated, the molecular pathogenesis of the disease is not understood. We examined cell cycle abnormalities in skin specimens and cultured cells derived from specific lesions of TSC patients with confirmed TSC1 or TSC2 mutations. None of the specimens used in this study showed loss of heterozygosity (LOH). We detected more cells positive for PCNA and fewer cells positive for MPP2 in the epidermis of TSC patients than in the epidermis of control patients without TSC. Incorporation of 5-bromo-2-deoxyuridine (BrdU) was similar in fibroblasts derived from TSC lesions and in normal human fibroblasts. These results suggest that the cell cycle of TSC cells shows a prolonged S phase. Flow cytometric analysis confirmed S phase prolongation in TSC cells. Many apoptotic cells were detected by a nick end labeling assay in both skin tissue and cultured fibroblasts derived from specific TSC lesions. Examination of cyclin levels showed increased nuclear cyclin A and cytoplasmic cyclin B and decreased nuclear cdc2 levels. We conclude that suppression of either TSC1 or TSC2 may change cyclin levels, prolong S phase and induce apoptotic cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11758789     DOI: 10.1007/s004030100259

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  8 in total

Review 1.  Lymphangioleiomyomatosis and TSC2-/- cells.

Authors:  Thomas N Darling; Gustavo Pacheco-Rodriguez; Alfredo Gorio; Elena Lesma; Cheryl Walker; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

2.  Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53.

Authors:  Chung-Han Lee; Ken Inoki; Magdalena Karbowniczek; Emmanuel Petroulakis; Nahum Sonenberg; Elizabeth Petri Henske; Kun-Liang Guan
Journal:  EMBO J       Date:  2007-10-25       Impact factor: 11.598

3.  Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.

Authors:  Laura C Armstrong; Grant Westlake; John P Snow; Bryan Cawthon; Eric Armour; Aaron B Bowman; Kevin C Ess
Journal:  Hum Mol Genet       Date:  2017-12-01       Impact factor: 6.150

4.  MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.

Authors:  Shaowei Li; Fumiko Takeuchi; Ji-an Wang; Christopher Fuller; Gustavo Pacheco-Rodriguez; Joel Moss; Thomas N Darling
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

5.  TSC loss distorts DNA replication programme and sensitises cells to genotoxic stress.

Authors:  Govind M Pai; Alexandra Zielinski; Dennis Koalick; Kristin Ludwig; Zhao-Qi Wang; Kerstin Borgmann; Helmut Pospiech; Ignacio Rubio
Journal:  Oncotarget       Date:  2016-12-20

6.  Defects in mTORC1 Network and mTORC1-STAT3 Pathway Crosstalk Contributes to Non-inflammatory Hepatocellular Carcinoma.

Authors:  Ting Li; Guohong Zhang; Linlin Wang; Susu Li; Xiaoping Xu; Yi Gao
Journal:  Front Cell Dev Biol       Date:  2020-04-07

7.  Ras and rheb signaling in survival and cell death.

Authors:  Anja Ehrkamp; Christian Herrmann; Raphael Stoll; Rolf Heumann
Journal:  Cancers (Basel)       Date:  2013-05-28       Impact factor: 6.639

8.  Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury.

Authors:  Assaad A Eid; Bridget M Ford; Basant Bhandary; Rita de Cassia Cavaglieri; Karen Block; Jeffrey L Barnes; Yves Gorin; Goutam Ghosh Choudhury; Hanna E Abboud
Journal:  Diabetes       Date:  2013-04-04       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.